Pyrazinamide

Class: Prodrug

Details of activity:	Anti-mycobacterial drug. Effective against Mycobacterium tuberculosis
Institute where first reported:	Novitium Pharma; Macleods Pharmaceuticals Limited (Approved by FDA in 2020)
Year first mentioned:	1972
Highest developmental phase:	Approved by FDA in 1971
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1=NC=C(C(=O)N)N=C1
Isomeric SMILES:	C1=CN=C(C=N1)C(=O)N
InChI:	InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
InChI Key:	IPEHBUMCGVEMRF-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/1046

External links:
Guide to Pharmacology:	pyrazinamide
Main Source:	https://mmbr.asm.org/content/84/2/e00070-19
Citation:	https://books.google.co.uk/books?id=aZc7AQAAQBAJ&pg=PA8&redir_esc=y#v=onepage&q&f=false